Page results
-
UCLH will play a vital role in a new respiratory virus study.
-
UCLH is continuing to scale up the number of services that offer Advice & Guidance, as well as identifying various improvements within the existing Advice & Guidance service. Over the last few months, UCLH has introduced 5 new specialties to the service, with additional specialties due to go live shortly.
-
This information is for children and young people with Type 1 diabetes, and their families, on how to manage high glucose levels when using an insulin pump.
-
The diabetes team have revisited their tips for managing diabetes over the Christmas holidays and updated them for 2022.
-
Read more about a UCLH patient saved by special 'before midnight' transfusions.
-
Information about the Therapeutic Plasma Exchange at NHNN for patients, carers, and families.
-
Holistic Needs Assessment (HNA): Information for people affected by cancer and blood conditions patient information leaflet
-
Our staff have rated UCLH as the top trust in England, improving on our ranking from last year when we were third best in England and top in London.
-
Among the many cancer clinical trials opening each year at UCLH, this year will see a focus on trials of personalised cancer treatments based on precision immunotherapies.
-
The NHS has become the first healthcare system in the world to provide a new blood group genotyping test which is set to transform care for patients living with sickle cell disorder and thalassaemia.
File results
-
FOI/2022/0494 - Treatment of Haemophilia A
-
FOI/2022/0495 - International recruitment
-
FOI/2022/0497 - Departments/ specialties that have functioning air-conditioning
-
FOI/2022/0502 - Asthma treatments
-
FOI/2022/0505 - Type of needles used for insulin administration to patients
-
FOI/2022/0506 - Node positive breast cancer patients undergoing Oncotype testing
-
FOI/2022/0514 - Infant deaths/ stillbirths and cremations
-
FOI/2022/0516 - Number of orthopaedic consultants at Trust
-
FOI/2022/0517 - Mobile phone and data contracts/ spend
-
FOI/2022/0519 - Melanoma treatments